
Kamada Ltd. KMDA
$ 6.75
-2.03%
Annual report 2024
added 10-25-2025
Kamada Ltd. Long Term Debt Current 2011-2025 | KMDA
Annual Long Term Debt Current Kamada Ltd.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.63 M | 1.38 M | 1.02 M | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.63 M | 1.02 M | 1.34 M |
Long Term Debt Current of other stocks in the Biotechnology industry
| Issuer | Long Term Debt Current | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
AgeX Therapeutics
AGE
|
428 K | $ 11.3 | -10.17 % | $ 12.2 K | - | |
|
Galera Therapeutics
GRTX
|
133 K | $ 0.14 | -32.59 % | $ 7.61 M | ||
|
CureVac N.V.
CVAC
|
3.47 M | $ 5.32 | -0.47 % | $ 990 M | ||
|
Axon Enterprise
AXON
|
9.45 M | $ 716.9 | -0.99 % | $ 54.3 B | ||
|
Caladrius Biosciences
CLBS
|
137 K | $ 0.43 | -16.75 % | $ 25.8 M | ||
|
Sorrento Therapeutics
SRNE
|
11.5 M | $ 0.27 | -29.58 % | $ 126 M | ||
|
BeiGene, Ltd.
BGNE
|
17.6 M | $ 184.71 | 0.49 % | $ 251 B | ||
|
ContraFect Corporation
CFRX
|
671 K | $ 1.47 | -5.16 % | $ 5.39 M | ||
|
Orchard Therapeutics plc
ORTX
|
6.42 M | $ 4.93 | 1.02 % | $ 90.8 M | ||
|
Advaxis
ADXS
|
166 K | $ 0.31 | -9.65 % | $ 45.9 M | ||
|
La Jolla Pharmaceutical Company
LJPC
|
154 K | $ 6.2 | - | $ 154 M | ||
|
Zymeworks
ZYME
|
1.31 M | $ 6.42 | - | $ 404 M | ||
|
Aeterna Zentaris
AEZS
|
271 K | $ 5.72 | 5.93 % | $ 314 M | ||
|
Immatics N.V.
IMTX
|
1.88 M | $ 9.21 | -4.86 % | $ 579 M | ||
|
Zosano Pharma Corporation
ZSAN
|
1.61 M | $ 0.56 | 7.23 % | $ 2.72 M | ||
|
Ayala Pharmaceuticals
AYLA
|
419 K | $ 0.5 | - | $ 7.46 M | ||
|
Krystal Biotech
KRYS
|
1.22 M | $ 203.41 | 2.81 % | $ 5.82 B | ||
|
Kiromic BioPharma
KRBP
|
685 K | $ 3.15 | 6.61 % | $ 3.08 M | ||
|
Albireo Pharma
ALBO
|
3.08 M | $ 44.15 | -0.23 % | $ 916 M | ||
|
Stealth BioTherapeutics Corp
MITO
|
9 M | $ 0.32 | - | $ 23.9 M | ||
|
Kaleido Biosciences
KLDO
|
2.63 M | $ 0.29 | -3.69 % | $ 12.4 M | ||
|
Mesoblast Limited
MESO
|
3.19 M | $ 15.61 | -3.1 % | $ 10.1 B | ||
|
Entasis Therapeutics Holdings
ETTX
|
704 K | $ 2.19 | - | $ 105 M | ||
|
Aptinyx
APTX
|
337 K | $ 0.06 | -39.0 % | $ 4.57 M | ||
|
Tyme Technologies
TYME
|
34.7 K | $ 0.31 | 8.07 % | $ 54 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
1.27 M | $ 0.39 | - | $ 26.5 M | ||
|
Celyad Oncology SA
CYAD
|
137 K | $ 0.47 | - | $ 12.5 M | ||
|
Brickell Biotech
BBI
|
49 K | $ 2.11 | -5.38 % | $ 6.06 M | ||
|
Genocea Biosciences
GNCA
|
2.35 M | $ 0.05 | -15.0 % | $ 3.04 M | ||
|
Codiak BioSciences
CDAK
|
2.66 M | $ 0.06 | -55.98 % | $ 2.15 M | ||
|
Concert Pharmaceuticals
CNCE
|
1.16 M | $ 8.37 | - | $ 401 M | ||
|
AIkido Pharma
AIKI
|
410 K | $ 3.17 | 1.93 % | $ 17.4 M | ||
|
Calithera Biosciences
CALA
|
1.37 M | $ 0.37 | -10.95 % | $ 876 K | ||
|
Forma Therapeutics Holdings
FMTX
|
5.12 M | $ 20.01 | - | $ 958 M | ||
|
Sierra Oncology
SRRA
|
368 K | $ 54.89 | -0.05 % | $ 1.34 B | ||
|
Regulus Therapeutics
RGLS
|
713 K | $ 8.16 | - | $ 155 M |